An Osmotically Driven Approach to Acebrophylline Delivery: Formulation, Optimization and Pharmaceutical Evaluation

Background: Acebrophylline is a bronchodilator and mucolytic used in asthma and chronic obstructive pulmonary disease (COPD) and is conventionally given twice daily. A controlled porosity osmotic pump (CPOP) tablet can extend its release without a laser-drilled orifice. Aim: To formulate acebrophylline CPOP tablets and evaluate the effect of osmogen and pore former levels on tablet properties and drug release. Materials and Methods: Core tablets (100 mg drug, 200 mg total weight) were prepared by direct compression using dextrose as osmogen (10, 20 and 30 mg) and spray dried lactose as diluent, and were dip-coated with ethyl cellulose containing PVP as pore former (12, 24 and 36 mg) and PEG as plasticizer, giving nine formulations (F1–F9). Drug–excipient compatibility was studied by FTIR, powder blends and tablets were evaluated, and in vitro release was studied in phosphate buffer pH 7.4. Release data of the optimised formulation were fitted to zero-order, first-order, Higuchi and Korsmeyer–Peppas models, and accelerated stability was assessed (40 ± 2 °C/75 ± 5% RH, 3 months). Results: The drug showed λmax at 274 nm (calibration y = 0.0203x + 0.0822; R² = 0.9976). FTIR showed no loss of the characteristic drug bands. Powder blends had good flow (Carr's index 13.33–14.04%; Hausner's ratio 1.15–1.16; angle of repose 27.8–28.7°). Tablets showed hardness of 6.1–7.3 kg/cm², friability of 0.24–0.42% and drug content of 96.9–99.5%. All formulations sustained release; F1, F2, F4 and F5 released 95.9–99.5% at 12 h, whereas F3, F7 (10 h) and F6, F8, F9 (8 h) reached 97.1–99.2% earlier. F5 gave the most gradual profile and the highest release at 12 h (99.5 ± 0.89%) and was selected as optimised. Its release fitted zero-order (R² = 0.998) and Korsmeyer–Peppas (R² = 0.997; n = 0.941, super case II transport) models best. Drug content of F5 remained within 95–105% after 3 months of accelerated storage (99.30 ± 0.70% to 98.96 ± 0.68%). Conclusion: Acebrophylline CPOP tablets provided controlled, near zero-order release over 12 h in vitro.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-14
DOI
https://doi.org/10.5281/zenodo.24216495
Primary Topic
Drug Solubulity and Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

An Osmotically Driven Approach to Acebrophylline Delivery: Formulation, Optimization and Pharmaceutical Evaluation

Syeda Sana Ilsa, P. M. Sameera
Zenodo (CERN European Organization for Nuclear Research)
Drug Solubulity and Delivery Systems
article

An Osmotically Driven Approach to Acebrophylline Delivery: Formulation, Optimization and Pharmaceutical Evaluation

Syeda Sana Ilsa, P. M. Sameera
article en

Abstract

Background: Acebrophylline is a bronchodilator and mucolytic used in asthma and chronic obstructive pulmonary disease (COPD) and is conventionally given twice daily. A controlled porosity osmotic pump (CPOP) tablet can extend its release without a laser-drilled orifice. Aim: To formulate acebrophylline CPOP tablets and evaluate the effect of osmogen and pore former levels on tablet properties and drug release. Materials and Methods: Core tablets (100 mg drug, 200 mg total weight) were prepared by direct compression using dextrose as osmogen (10, 20 and 30 mg) and spray dried lactose as diluent, and were dip-coated with ethyl cellulose containing PVP as pore former (12, 24 and 36 mg) and PEG as plasticizer, giving nine formulations (F1–F9). Drug–excipient compatibility was studied by FTIR, powder blends and tablets were evaluated, and in vitro release was studied in phosphate buffer pH 7.4. Release data of the optimised formulation were fitted to zero-order, first-order, Higuchi and Korsmeyer–Peppas models, and accelerated stability was assessed (40 ± 2 °C/75 ± 5% RH, 3 months). Results: The drug showed λmax at 274 nm (calibration y = 0.0203x + 0.0822; R² = 0.9976). FTIR showed no loss of the characteristic drug bands. Powder blends had good flow (Carr's index 13.33–14.04%; Hausner's ratio 1.15–1.16; angle of repose 27.8–28.7°). Tablets showed hardness of 6.1–7.3 kg/cm², friability of 0.24–0.42% and drug content of 96.9–99.5%. All formulations sustained release; F1, F2, F4 and F5 released 95.9–99.5% at 12 h, whereas F3, F7 (10 h) and F6, F8, F9 (8 h) reached 97.1–99.2% earlier. F5 gave the most gradual profile and the highest release at 12 h (99.5 ± 0.89%) and was selected as optimised. Its release fitted zero-order (R² = 0.998) and Korsmeyer–Peppas (R² = 0.997; n = 0.941, super case II transport) models best. Drug content of F5 remained within 95–105% after 3 months of accelerated storage (99.30 ± 0.70% to 98.96 ± 0.68%). Conclusion: Acebrophylline CPOP tablets provided controlled, near zero-order release over 12 h in vitro.

Zenodo (CERN European Organization for Nuclear Research)
Drug Solubulity and Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon